NCT02130024 - A Comparison of Ranibizumab and Aflibercept for the Development of Geographic Atrophy in (Wet) AMD Patients | Biotech Hunter

Enrollment

281

Participants

Timeline

Start Date

April 11, 2014

Primary Completion Date

November 15, 2017

Study Completion Date

November 15, 2017

Conditions

Age-Related Macular Degeneration

Interventions

DRUG

Ranibizumab 0.5 mg

Administered as an intravitreal injection

DRUG

Aflibercept 2.0 mg

Administered as an intravitreal injection

Trial Locations (22)

2000

Novartis Investigative Site, Sydney

2035

Novartis Investigative Site, Strathfield

2067

Novartis Investigative Site, Chatswood

2100

Novartis Investigative Site, Brookvale

2135

Novartis Investigative Site, Strathfield

2145

Novartis Investigative Site, Westmead

2150

Novartis Investigative Site, Parramatta

2220

Novartis Investigative Site, Hurtsville

2640

Novartis Investigative Site, Albury

3065

Novartis Investigative Site, Parkville

3144

Novartis Investigative Site, Malvern

3168

Novartis Investigative Site, Clayton

4020

Novartis Investigative Site, Redcliffe

4101

Novartis Investigative Site, South Brisbane

4215

Novartis Investigative Site, Southport

4510

Novartis Investigative Site, Caboolture

5000

Novartis Investigative Site, Adelaide

6008

Novartis Investigative Site, Subiaco

6009

Novartis Investigative Site, Nedlands

7249

Novartis Investigative Site, South Launceston

Unknown

Novartis Investigative Site, Mona Vale

AUSTRALIA

Novartis Investigative Site, Sydney